Mesoblast Ltd Ads (MESO)

$12.00 0.75 (6.67%)

10:42 EDT MESO Stock Quote Delayed 30 Minutes

Volume:

Previous Close -

Market Cap 1.14B

PE Ratio -

EPS -

Volume (Avg. Vol.) 179,090

Day's Range 11.61 - 12.13

52-Week Range 3.12 - 21.28

Dividend & Yield N/A (N/A)

MESO Stock Predictions, Articles, and Mesoblast Ltd Ads News

From the Web

LAWSUITS FILED AGAINST AYX, NKLA and MESO - Jakubowitz Law Pursues Shareholders Claims

From Jakubowitz Law Oct 19, 2020

NEW YORK, NY / ACCESSWIRE / October 19, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't

First Week of MESO December 18th Options Trading

From Market News Video Oct 19, 2020

Investors in Mesoblast Ltd (MESO) saw new options begin trading this week, for the December 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MESO options chain for the new December 18th contracts and identified one put and one call contract of particular interest.

Why Brinker International Shares Look Tasty

From Barron's Oct 16, 2020

Margin improvements and cost cuts could produce earnings above $5 a share when the pandemic ends. Also, Wall Street opinions on the stocks of UnitedHealth Group, PNC Financial Services, Albertsons, and Mesoblast

Are Options Traders Betting on a Big Move in Mesoblast (MESO) Stock?

From Zacks Investment Research Oct 14, 2020

Investors need to pay close attention to Mesoblast (MESO) stock based on the movements in the options market lately.

MESO Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Mesoblast Limited Shareholders of Class Action and Lead Plaintiff Deadline: December 7, 2020

From BusinessInsider Oct 13, 2020

NEW YORK, Oct. 13, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit ...

Late-stage study of Mesoblast cell therapy in COVID-19 excel 50% enrollment (NASDAQ:MESO)

From Seeking Alpha Oct 13, 2020

Mesoblast Limited (NASDAQ:MESO) +2% premarket says that the randomized controlled Phase 3 trial of remestemcel-L, an allogeneic mesenchymal stem cell product derived from bone marrow, in COVID-19 patients with moderate-to-severe acute respiratory distress syndrome (ARDS) has surpassed 50% enrollment.

Navellier Ratings

Powered by Portfolio Grader

Total Grade

B

Buy